To assess the diagnostic potential of bidirectional axial transmission (BDAT) ultrasound, and high-resolution peripheral quantitative computed tomography (HR-pQCT) in X-linked hypophosphatemia (XLH, OMIM #307800), a rare genetic disorder of phosphate metabolism caused by mutations in the gene. BDAT bone ultrasound was performed at the non-dominant distal radius (33% relative to distal head) and the central left tibia (50%) in eight XLH patients aged between 4.2 and 20.8 years and compared to twenty-nine healthy controls aged between 5.8 and 22.4 years. In eighteen controls, only radius measurements were performed. Four patients and four controls opted to participate in HR-pQCT scanning of the ultradistal radius and tibia. Bone ultrasound was feasible in patients and controls as young as 4 years of age. The velocity of the first arriving signal (ν) in BDAT ultrasound was significantly lower in XLH patients compared to healthy controls: In the radius, mean ν of XLH patients and controls was 3599 ± 106 and 3866 ± 142 m/s, respectively (-6.9%; < 0.001). In the tibia, it was 3578 ± 129 and 3762 ± 124 m/s, respectively (-4.9%; = 0.006). HR-pQCT showed a higher trabecular thickness in the tibia of XLH patients (+16.7%; = 0.021). Quantitative bone ultrasound revealed significant differences in cortical bone quality of young XLH patients as compared to controls. Regular monitoring of XLH patients by a radiation-free technology such as BDAT might provide valuable information on bone quality and contribute to the optimization of treatment. Further studies are needed to establish this affordable and time efficient method in the XLH patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296046PMC
http://dx.doi.org/10.3389/fendo.2020.00355DOI Listing

Publication Analysis

Top Keywords

xlh patients
28
bone ultrasound
12
patients controls
12
xlh
9
patients
9
bdat ultrasound
8
healthy controls
8
controls radius
8
patients compared
8
bone quality
8

Similar Publications

X-linked hypophosphataemia (XLH) is a rare metabolic bone disorder caused by pathogenic variants in the PHEX gene, which is predominantly expressed in osteoblasts, osteocytes and odontoblasts. XLH is characterized by increased synthesis of the bone-derived phosphaturic hormone fibroblast growth factor 23 (FGF23), which results in renal phosphate wasting with consecutive hypophosphataemia, rickets, osteomalacia, disproportionate short stature, oral manifestations, pseudofractures, craniosynostosis, enthesopathies and osteoarthritis. Patients with XLH should be provided with multidisciplinary care organized by a metabolic bone expert.

View Article and Find Full Text PDF

Clinical, Radiographic, and Molecular Analysis of Patients with X-Linked Hypophosphatemic Rickets: Looking for Phenotype-Genotype Correlation.

Diagnostics (Basel)

January 2025

Departamento de Medicina Genómica, Instituto Nacional de Rehabilitación, Calzada México-Xochimilco 289, Col. Arenal de Guadalupe, Ciudad de México 14389, Mexico.

Background/objectives: X-linked hypophosphataemic rickets (XLH) represents the most frequent type of rickets from genetic origin, it is caused by mutations on the gene. The main clinical manifestations are short stature and bone deformities. Phenotype variation is observed at the intrafamily and interfamily level.

View Article and Find Full Text PDF

Objective: To examine the evidence addressing the management of X-linked hypophosphatemia (XLH) in children to inform treatment recommendations.

Methods: We searched Embase, MEDLINE, Web of Science, and Cochrane Central up to May 2023. Eligible studies included RCTs and observational studies of individuals less than 18yrs with clinically or genetically confirmed XLH.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate the most reliable evidence for managing X-linked hypophosphatemia (XLH) in adults to help shape treatment recommendations.
  • After reviewing over 4,000 records, only one clinical trial and two observational studies met the criteria, showing that burosumab likely helps with pain from fractures but has a limited effect on other symptoms like fatigue and stiffness.
  • There are currently no strong comparisons between burosumab and conventional treatments, highlighting a significant gap in data regarding their long-term effectiveness on important patient outcomes.
View Article and Find Full Text PDF

Over 70 intragenic copy-number variations (CNVs) of PHEX have been identified in patients with X-linked hypophosphatemia (XLH). However, the underlying mechanism of these CNVs has been poorly investigated. Furthermore, although PHEX undergoes X chromosome inactivation (XCI), the association between XLH in women with heterozygous PHEX variants and skewed XCI remains unknown.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!